TY  - JOUR
AU  - Doneva, Miglena
AU  - Milushewa, Petya
AU  - Dimitrova, Maria
AU  - Kamusheva,  Maria
AU  - Stoitchkov, Jordan
AU  - Petrova, Guenka
AU  - Naydenova, Kremena
AU  - Krusheva, Borislava
AU  - Dimitrov, Vasil
AU  - Lakić, Dragana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4202
AB  - This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.
PB  - Taylor and Francis Ltd.
T2  - Biotechnology and Biotechnological Equipment
T1  - Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study
VL  - 36
IS  - 1
SP  - 478
EP  - 485
DO  - 10.1080/13102818.2022.2098818
ER  - 

@article{
author = "Doneva, Miglena and Milushewa, Petya and Dimitrova, Maria and Kamusheva,  Maria and Stoitchkov, Jordan and Petrova, Guenka and Naydenova, Kremena and Krusheva, Borislava and Dimitrov, Vasil and Lakić, Dragana",
year = "2022",
abstract = "This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.",
publisher = "Taylor and Francis Ltd.",
journal = "Biotechnology and Biotechnological Equipment",
title = "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study",
volume = "36",
number = "1",
pages = "478-485",
doi = "10.1080/13102818.2022.2098818"
}

Doneva, M., Milushewa, P., Dimitrova, M., Kamusheva, M., Stoitchkov, J., Petrova, G., Naydenova, K., Krusheva, B., Dimitrov, V.,& Lakić, D.. (2022). Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment
Taylor and Francis Ltd.., 36(1), 478-485.
https://doi.org/10.1080/13102818.2022.2098818

Doneva M, Milushewa P, Dimitrova M, Kamusheva M, Stoitchkov J, Petrova G, Naydenova K, Krusheva B, Dimitrov V, Lakić D. Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study. in Biotechnology and Biotechnological Equipment. 2022;36(1):478-485.
doi:10.1080/13102818.2022.2098818 .

Doneva, Miglena, Milushewa, Petya, Dimitrova, Maria, Kamusheva,  Maria, Stoitchkov, Jordan, Petrova, Guenka, Naydenova, Kremena, Krusheva, Borislava, Dimitrov, Vasil, Lakić, Dragana, "Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study" in Biotechnology and Biotechnological Equipment, 36, no. 1 (2022):478-485,
https://doi.org/10.1080/13102818.2022.2098818 . .

TY  - JOUR
AU  - Turcu-Stiolica, Adina
AU  - Kamusheva, Maria
AU  - Bogdan, Maria
AU  - Tadić, Ivana
AU  - Harasani, Klejda
AU  - Subtirelu, Mihaela-Simona
AU  - Meca, Andreea-Daniela
AU  - Šesto, Sofia
AU  - Odalović, Marina
AU  - Arsić, Jasmina
AU  - Stojkov, Svetlana
AU  - Terzieva, Emili
AU  - Petrova, Guenka
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4007
AB  - Community pharmacists expanded their roles and engaged in vaccination services in many countries around the world, but not in Balkan countries. This research aimed to assess the perceptions of pharmacists on involvement in the coronavirus disease (COVID-19) vaccine administration in four Balkan countries (Albania, Bulgaria, Romania, and Serbia). A cross-sectional survey was conducted using an online questionnaire that was distributed to community pharmacists across these countries between February and March 2021. A total of 636 community pharmacists were included in the analysis of the survey. The willingness to administer vaccines for COVID-19 (or other vaccines well established in the practice, like a flu vaccine) in community pharmacies is significantly different among the countries: the pharmacists from Albania were more willing to administer vaccines. The factors associated with the eagerness to vaccinate are almost the same among the countries: the lack of training in the faculty classes and the lack of a special place where to administer vaccines. Additional significant factors were found in Bulgaria (pharmacists from independent pharmacies wanted more than the pharmacists working in chain pharmacies to administer vaccines) and in Serbia (male pharmacists agreed more with administering vaccines than female pharmacists). Further national reforms are needed for adopting the expanding role of community pharmacists.
PB  - Frontiers Media S.A.
T2  - Frontiers in Public Health
T1  - Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries
VL  - 9
DO  - 10.3389/fpubh.2021.766146
ER  - 

@article{
author = "Turcu-Stiolica, Adina and Kamusheva, Maria and Bogdan, Maria and Tadić, Ivana and Harasani, Klejda and Subtirelu, Mihaela-Simona and Meca, Andreea-Daniela and Šesto, Sofia and Odalović, Marina and Arsić, Jasmina and Stojkov, Svetlana and Terzieva, Emili and Petrova, Guenka",
year = "2021",
abstract = "Community pharmacists expanded their roles and engaged in vaccination services in many countries around the world, but not in Balkan countries. This research aimed to assess the perceptions of pharmacists on involvement in the coronavirus disease (COVID-19) vaccine administration in four Balkan countries (Albania, Bulgaria, Romania, and Serbia). A cross-sectional survey was conducted using an online questionnaire that was distributed to community pharmacists across these countries between February and March 2021. A total of 636 community pharmacists were included in the analysis of the survey. The willingness to administer vaccines for COVID-19 (or other vaccines well established in the practice, like a flu vaccine) in community pharmacies is significantly different among the countries: the pharmacists from Albania were more willing to administer vaccines. The factors associated with the eagerness to vaccinate are almost the same among the countries: the lack of training in the faculty classes and the lack of a special place where to administer vaccines. Additional significant factors were found in Bulgaria (pharmacists from independent pharmacies wanted more than the pharmacists working in chain pharmacies to administer vaccines) and in Serbia (male pharmacists agreed more with administering vaccines than female pharmacists). Further national reforms are needed for adopting the expanding role of community pharmacists.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Public Health",
title = "Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries",
volume = "9",
doi = "10.3389/fpubh.2021.766146"
}

Turcu-Stiolica, A., Kamusheva, M., Bogdan, M., Tadić, I., Harasani, K., Subtirelu, M., Meca, A., Šesto, S., Odalović, M., Arsić, J., Stojkov, S., Terzieva, E.,& Petrova, G.. (2021). Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. in Frontiers in Public Health
Frontiers Media S.A.., 9.
https://doi.org/10.3389/fpubh.2021.766146

Turcu-Stiolica A, Kamusheva M, Bogdan M, Tadić I, Harasani K, Subtirelu M, Meca A, Šesto S, Odalović M, Arsić J, Stojkov S, Terzieva E, Petrova G. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. in Frontiers in Public Health. 2021;9.
doi:10.3389/fpubh.2021.766146 .

Turcu-Stiolica, Adina, Kamusheva, Maria, Bogdan, Maria, Tadić, Ivana, Harasani, Klejda, Subtirelu, Mihaela-Simona, Meca, Andreea-Daniela, Šesto, Sofia, Odalović, Marina, Arsić, Jasmina, Stojkov, Svetlana, Terzieva, Emili, Petrova, Guenka, "Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries" in Frontiers in Public Health, 9 (2021),
https://doi.org/10.3389/fpubh.2021.766146 . .

TY  - JOUR
AU  - Kamusheva, Maria
AU  - Manova, Manoela
AU  - Savova, Alexandra
AU  - Petrova, Guenka
AU  - Mitov, Konstantin
AU  - Harsanyi, Andras
AU  - Kalo, Zoltan
AU  - Marky, Kristof
AU  - Kawalec, Pawel
AU  - Angelovska, Bistra
AU  - Lakić, Dragana
AU  - Tesar, Tomas
AU  - Draganić, Pero
AU  - Geitona, Mary
AU  - Hatziko, Magdalini
AU  - Paveliu, Marian S.
AU  - Mannik, Agnes
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3195
AB  - Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Pharmacology
T1  - Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
VL  - 9
DO  - 10.3389/fphar.2018.00795
ER  - 

@article{
author = "Kamusheva, Maria and Manova, Manoela and Savova, Alexandra and Petrova, Guenka and Mitov, Konstantin and Harsanyi, Andras and Kalo, Zoltan and Marky, Kristof and Kawalec, Pawel and Angelovska, Bistra and Lakić, Dragana and Tesar, Tomas and Draganić, Pero and Geitona, Mary and Hatziko, Magdalini and Paveliu, Marian S. and Mannik, Agnes",
year = "2018",
abstract = "Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Pharmacology",
title = "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries",
volume = "9",
doi = "10.3389/fphar.2018.00795"
}

Kamusheva, M., Manova, M., Savova, A., Petrova, G., Mitov, K., Harsanyi, A., Kalo, Z., Marky, K., Kawalec, P., Angelovska, B., Lakić, D., Tesar, T., Draganić, P., Geitona, M., Hatziko, M., Paveliu, M. S.,& Mannik, A.. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology
Frontiers Media Sa, Lausanne., 9.
https://doi.org/10.3389/fphar.2018.00795

Kamusheva M, Manova M, Savova A, Petrova G, Mitov K, Harsanyi A, Kalo Z, Marky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganić P, Geitona M, Hatziko M, Paveliu MS, Mannik A. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. in Frontiers in Pharmacology. 2018;9.
doi:10.3389/fphar.2018.00795 .

Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Petrova, Guenka, Mitov, Konstantin, Harsanyi, Andras, Kalo, Zoltan, Marky, Kristof, Kawalec, Pawel, Angelovska, Bistra, Lakić, Dragana, Tesar, Tomas, Draganić, Pero, Geitona, Mary, Hatziko, Magdalini, Paveliu, Marian S., Mannik, Agnes, "Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries" in Frontiers in Pharmacology, 9 (2018),
https://doi.org/10.3389/fphar.2018.00795 . .

TY  - JOUR
AU  - Kamusheva, Maria
AU  - Georgieva, Svetla
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Stoimenova, Assena
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1965
AB  - The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria
VL  - 27
IS  - 3
SP  - 3896
EP  - 3900
DO  - 10.5504/BBEQ.2013.0029
ER  - 

@article{
author = "Kamusheva, Maria and Georgieva, Svetla and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Stoimenova, Assena and Petrova, Guenka",
year = "2013",
abstract = "The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria",
volume = "27",
number = "3",
pages = "3896-3900",
doi = "10.5504/BBEQ.2013.0029"
}

Kamusheva, M., Georgieva, S., Lakić, D., Mitov, K., Savova, A., Stoimenova, A.,& Petrova, G.. (2013). A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 27(3), 3896-3900.
https://doi.org/10.5504/BBEQ.2013.0029

Kamusheva M, Georgieva S, Lakić D, Mitov K, Savova A, Stoimenova A, Petrova G. A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment. 2013;27(3):3896-3900.
doi:10.5504/BBEQ.2013.0029 .

Kamusheva, Maria, Georgieva, Svetla, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Stoimenova, Assena, Petrova, Guenka, "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria" in Biotechnology & Biotechnological Equipment, 27, no. 3 (2013):3896-3900,
https://doi.org/10.5504/BBEQ.2013.0029 . .

TY  - JOUR
AU  - Georgieva, Svetla
AU  - Kamusheva, Maria
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Petrova, Guenka
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1729
AB  - The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - The health related quality of life for kidney transplant patients in Bulgaria - A pilot study
VL  - 26
IS  - 3
SP  - 3062
EP  - 3065
DO  - 10.5504/BBEQ.2012.0005
ER  - 

@article{
author = "Georgieva, Svetla and Kamusheva, Maria and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Petrova, Guenka",
year = "2012",
abstract = "The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study",
volume = "26",
number = "3",
pages = "3062-3065",
doi = "10.5504/BBEQ.2012.0005"
}

Georgieva, S., Kamusheva, M., Lakić, D., Mitov, K., Savova, A.,& Petrova, G.. (2012). The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 26(3), 3062-3065.
https://doi.org/10.5504/BBEQ.2012.0005

Georgieva S, Kamusheva M, Lakić D, Mitov K, Savova A, Petrova G. The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment. 2012;26(3):3062-3065.
doi:10.5504/BBEQ.2012.0005 .

Georgieva, Svetla, Kamusheva, Maria, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Petrova, Guenka, "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study" in Biotechnology & Biotechnological Equipment, 26, no. 3 (2012):3062-3065,
https://doi.org/10.5504/BBEQ.2012.0005 . .